Clinical Pharmacology of Corticosteroids

References

1. 1.↵
   1. Gupta P,
   2. Bhatia V

   . Corticosteroid physiology and principles of therapy. Indian J Pediatr 2008;75(10):1039–1044.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Shaikh S,
   2. Verma H,
   3. Yadav M,
   4. Jauhari M,
   5. Bullangowda J

   , Applications of steroid in clinical practice: a review. ISRN Anesthesiol 2012, vol. 2012, Article ID 985495, 11 pages, 2012. doi:10.5402/2012/985495.

   OpenUrlCrossRef
3. 3.↵
   1. Becker DE

   . Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog 2013;60(1):25–31; quiz 32.

   OpenUrl
4. 4.↵
   1. Annane D

   . Adrenal insufficiency in sepsis. Curr Pharm Des 2008;14(19):1882–1886.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Taylor DR,
   2. Hancox RJ

   . Interactions between corticosteroids and beta agonists. Thorax 2000;55:595–602.

   OpenUrlFREE Full Text
6. 6.↵
   1. Derendorf H,
   2. Nave R,
   3. Drollmann A,
   4. Cerasoli F,
   5. Wurst W

   . Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042–1050.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Raissy HH,
   2. Kelly HW,
   3. Harkins M,
   4. Szefler SJ

   . Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 2013;187(8):798–803.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Barnes PJ

   . How Do Corticosteroids Work in Asthma? Ann Intern Med 2003;139(5 Pt 1):359–370.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Ye Q,
   2. He XO,
   3. D'Urzo A

   . A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther 2017;3(1):1–18.

   OpenUrl
10. 10.↵
    1. Ericson-Neilsen W,
    2. Kaye AD

    . Steroids: pharmacology, complications, and practice delivery issues. Ochsner J 2014;14(2):203–207.

    OpenUrl
11. 11.↵
    1. Moss GP

    . Nomenclature of steroids. Pure Appl Chem 1989;61(10):1783–1822.

    OpenUrl
12. 12.↵
    1. Daley-Yates PT

    . Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol 2015;80(3):372–380.

    OpenUrl
13. 13.↵
    1. Swartz SL,
    2. Dluhy RG

    . Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978;16(3):238–255.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Liu D,
    2. Ahmet A,
    3. Ward L,
    4. Krishnamoorthy P,
    5. Mandelcorn ED,
    6. Leigh R,
    7. et al

    . A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9(1):30–37.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Waljee AK,
    2. Rogers MA,
    3. Lin P,
    4. Singal AG,
    5. Stein JD,
    6. Marks RM,
    7. et al

    . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017;357:j1415.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Lipworth BJ

    . Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993;58(2):173–209.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    National Institute for Health and Care Excellence (2017). List of Drug Interactions: Corticosteroids. Evidence Search. Accessed 16 May 2017.
18. 18.↵
    1. Johnson M

    . Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998;101(4 Pt 2):S434–S439.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Dalby RN,
    2. Byron PR,
    3. Peart J,
    4. Farr SJ

    1. Brattsand R

    . Development of inhaled steroids: past, present and prospects. In: Dalby RN, Byron PR, Peart J, Farr SJ, editors. Respiratory Drug Delivery. Richmond, VA: Virginia Commonwealth University; 2002:1–14.
20. 20.↵
    1. Phillips K,
    2. Oborne J,
    3. Lewis S,
    4. Harrison TW,
    5. Tattersfield AE

    . Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004;59(1):26–30.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Yeo SH,
    2. Aggarwal B,
    3. Shantakumar S,
    4. Mulgirigama A,
    5. Daley-Yates P

    . Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma. Expert Rev Respir Med 2017;11(10):763–778.

    OpenUrl
22. 22.↵
    1. Thorsson L,
    2. Edsbäcker S,
    3. Conradson TB

    . Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7(10):1839–1844.

    OpenUrlAbstract
23. 23.↵
    1. van der Molen T,
    2. Kocks JW

    . The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide? NPJ Prim Care Respir Med 2014;24:14013.

    OpenUrl
24. 24.↵
    1. Kramer S,
    2. Rottier BL,
    3. Scholten RJ,
    4. Boluyt N

    . Ciclesonide versus other inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2013;(2):CD010352.
25. 25.↵
    1. Derendorf H,
    2. Hochhaus G,
    3. Meibohm B,
    4. Möllmann H,
    5. Barth J

    . Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998;101(4 Pt 2):S440–S446.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Sobande PO,
    2. Kercsmar CM

    . Inhaled corticosteroids in asthma management. Respir Care 2008;53(5):625–633; discussion 633-634.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. García-Arieta A

    . Sensitive studies with a significant dose-response curve for inhaled corticosteroids to investigate equivalent relative potency are feasible. Br J Clin Pharmacol 2011;72(5):832–833; author reply 834-835.

    OpenUrlPubMed
28. 28.↵
    1. Colice GL

    . Comparing inhaled corticosteroids. Respir Care 2000;45(7):846–853.

    OpenUrlPubMed
29. 29.↵
    1. Kelly HW

    . Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009;43(3):519–527.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Zitt MJ

    . Advances in inhaled corticosteroid pharmacology. Allergy Asthma Proc 2007;28(2):114–124.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Geddes DM

    . Inhaled corticosteroids: benefits and risks. Thorax 1992;47(6):404–407.

    OpenUrlFREE Full Text
32. 32.↵
    1. Currie GP,
    2. Fowler SJ,
    3. Lipworth BJ

    . Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol 2003;90(2):194–198.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Martin RJ,
    2. Szefler SJ,
    3. Chinchilli VM,
    4. Kraft M,
    5. Dolovich M,
    6. Boushey HA,
    7. et al

    . Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165(10):1377–1383.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Kelly HW,
    2. Sternberg AL,
    3. Lescher R,
    4. Fuhlbrigge AL,
    5. Williams P,
    6. Zeiger RS,
    7. et al

    ; CAMP Research Goup. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012;367(10):904–912.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. Loke YK,
    2. Blanco P,
    3. Thavarajah M,
    4. Wilson AM

    . Impact of inhaled corticosteroids on growth in children with asthma: Systematic review and meta-analysis. PLoS One 2015;10(7):e0133428.

    OpenUrl
36. 36.↵
    1. Bourbeau J,
    2. Aaron SD,
    3. Barnes NC,
    4. Davis KJ,
    5. Lacasse Y,
    6. Nadeau G

    . Evaluating the risk of pneumonia with inhaled corticosteroids in COPD: Retrospective database studies have their limitations SA. Respir Med 2017;123:94–97.

    OpenUrl
37. 37.↵
    1. Suissa S,
    2. Patenaude V,
    3. Lapi F,
    4. Ernst P

    . Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68(11):1029–1036.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Kew KM,
    2. Seniukovich A

    . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;(3):CD010115.
39. 39.↵
    1. Qian CJ,
    2. Coulombe J,
    3. Suissa S,
    4. Ernst P

    . Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. Br J Clin Pharmacol 2017;83(9):2077–2086.

    OpenUrl
40. 40.↵
    1. Saberi P,
    2. Phengrasamy T,
    3. Nguyen DP

    . Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med 2013;14(9):519–529.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Drummond MB,
    2. Kunisaki KM,
    3. Huang L

    . Obstructive lung diseases in HIV: A clinical review and identification of key future research needs. Semin Respir Crit Care Med 2016;37(2):277–288.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Daveluy A,
    2. Raignoux C,
    3. Miremont-Salamé G,
    4. Girodet PO,
    5. Moore N,
    6. Haramburu F,
    7. Molimard M

    . Drug interactions between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Pharmacol 2009;65(7):743–745.

    OpenUrlCrossRefPubMed
43. 43.↵
    GOLD Science Committee. Global Initiative for Chronic Obstructive Lung Disease. 2018 ed. Global Initiative for Chronic Obstructive Lung Disease, Inc; 2018. http://copdgold.org. Accessed December 31, 2017.
44. 44.↵
    1. Babu KS,
    2. Kastelik JA,
    3. Morjaria JB

    . Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol 2014;78(2):282–300.

    OpenUrl
45. 45.↵
    1. Leuppi JD,
    2. Schuetz P,
    3. Bingisser R,
    4. Bodmer M,
    5. Briel M,
    6. Drescher T,
    7. et al

    . Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013;309(21):2223–2231.

    OpenUrlCrossRefPubMedWeb of Science